Alzheimer Disease Clinical Trial
— e-TimeOfficial title:
Role of the Striatum and Hippocampus on Different Time Scales
Time processing is fundamental to survival and goal reaching in humans. Different time scales (seconds, minutes, and beyond) are processed through specific cognitive processes involving different neural representations. It is generally agreed that time scale in seconds-to-minutes range named "interval timing" would be anatomically linked to the striatum. Indeed, it is possible to demonstrate a deficit of interval timing processes in patients suffering from striatal damage (Huntington's disease). However, recent findings show involvement of a second brain structure, the hippocampus, in interval timing processing in the minutes range, suggesting an interaction between the striatum and hippocampus. Presumably, patients with hippocampal damage (Alzheimer's disease) would specifically show a decrease in performance for this minutes-range time scale. This study aims to provide a better understanding of the role of the striatum in the treatment of time and its interactions with other brain structures such as the hippocampus. More specifically, it is unclear whether the striatum plays a platform role that would always be involved regardless of the time scale, as suggested by the unified model of time or whether different brain structures is solicited according to the time scale, as suggested by the modular system model. In order to elucidate these issues, a potential double dissociation between brain structures and time scales will be tested.
Status | Recruiting |
Enrollment | 104 |
Est. completion date | March 30, 2026 |
Est. primary completion date | March 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Huntington's disease gene carriers - Patient included in the BioHD protocol - Age from 18 to 90 years old - Symptomatic patient - TFC = 11 - UHDRS motor> 5 - Native language: French - Affiliation to a social security or to another social protection - Signature of informed consent • Patients with Alzheimer's disease - MMS from 20 to 26 (included) - Age: from 60 to 90 years old - Native language: French - Progressive deterioration of memory reported by patient or caregiver for more than 6 months - Profile at RL /RI 16: no significant improvement with indexing - Episodic memory disorder isolated or associated with other cognitive disorders - MRI: Atrophy of the median temporal lobe - Affiliation to a social security or to another social protection - Signature of informed consent • Healthy subjects - Healthy subject included in the BioHD protocol - MMS = 26 - Age from 18 to 90 years old - Native language: French - Affiliation to a social security or to another social protection - Signature of informed consent Exclusion Criteria: - Huntington's disease gene carriers - Intellectual deterioration preventing understanding of the protocol - Other dementia than Huntington's disease - Patient living alone at home - Major depression - Patient under legal protection - Patient deprived of liberty - Pregnant or breastfeeding woman, situation known to the investigator - Inability to handle an electronic tablet - Patients with Alzheimer's disease - Intellectual deterioration preventing understanding of the protocol - Patient living alone at home - Sudden onset of memory impairment - Early onset of the following symptoms: difficulty in walking, convulsions, changes in behavior - Focal neurological characteristics including hemiparesis, sensory loss, visual field deficit - Early extrapyramidal sign - Other dementia than Alzheimer's disease - Major depression - Cerebrovascular disease - Toxic, metabolic or infectious anomaly - Patient under legal protection - Patient deprived of liberty - Pregnant or breastfeeding woman, situation known to the investigator - Inability to handle an electronic tablet - Healthy subjects - Intellectual deterioration preventing understanding of the protocol - Known neurological or psychiatric illness - Patient under legal protection - Subject deprived of liberty - Pregnant or breastfeeding woman, situation known to the investigator - Inability to handle an electronic tablet |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hôpitaux de Paris - Hôpital Henri Mondor | Créteil |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ability to discriminate durations | Ability to discriminate durations of a few seconds and durations of the order of minutes | 25 months and 10 days | |
Secondary | Risks's prediction of temporal disorientation. | Analysis of the answers (true/false) to the questionnaire assessing temporal orientation in daily life | 26 months | |
Secondary | Identification of neural correlations with temporal perception tests | Brain magnetic resonance imaging analysis | 27 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |